Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRIONASDAQ:FEMYNASDAQ:PYPDNASDAQ:WOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRIODarioHealth$0.70+0.7%$0.68$0.50▼$1.57$31.11M1.55277,716 shs262,730 shsFEMYFemasys$1.02-3.8%$1.16$0.86▼$1.80$27.79M-2.52236,472 shs214,018 shsPYPDPolyPid$2.79+9.8%$2.70$2.30▼$4.67$25.89M1.2517,096 shs49,241 shsWOKWORK Medical Technology Group LTD Ordinary Shares$0.87+8.8%$0.51$0.36▼$8.45$12.70MN/A1.19 million shs437,450 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRIODarioHealth+1.30%-2.51%-2.74%+0.59%-52.54%FEMYFemasys-3.77%-3.77%-12.82%-35.03%-12.82%PYPDPolyPid+9.89%0.00%+6.49%-13.62%-37.86%WOKWORK Medical Technology Group LTD Ordinary Shares+8.78%+26.25%+110.65%+20.83%+86,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRIODarioHealth1.7096 of 5 stars3.30.00.00.02.50.81.3FEMYFemasys3.3494 of 5 stars3.55.00.00.02.62.50.6PYPDPolyPid2.1627 of 5 stars3.63.00.00.01.91.70.0WOKWORK Medical Technology Group LTD Ordinary SharesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRIODarioHealth 2.67Moderate Buy$2.00185.71% UpsideFEMYFemasys 3.00Buy$8.67749.67% UpsidePYPDPolyPid 3.25Buy$11.33306.21% UpsideWOKWORK Medical Technology Group LTD Ordinary Shares 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WOK, DRIO, PYPD, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/28/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/19/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.003/13/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/11/2025DRIODarioHealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRIODarioHealth$28.03M1.11N/AN/A$2.14 per share0.33FEMYFemasys$1.70M16.35N/AN/A$0.85 per share1.20PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/AWOKWORK Medical Technology Group LTD Ordinary Shares$11.51M1.10N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRIODarioHealth-$59.43M-$0.56N/AN/AN/A-205.62%-72.16%-40.74%8/14/2025 (Estimated)FEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%8/13/2025 (Estimated)WOKWORK Medical Technology Group LTD Ordinary SharesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest WOK, DRIO, PYPD, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRIODarioHealthN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/AWOKWORK Medical Technology Group LTD Ordinary SharesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRIODarioHealth0.351.571.32FEMYFemasys0.863.943.26PYPDPolyPid0.081.311.00WOKWORK Medical Technology Group LTD Ordinary SharesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRIODarioHealth33.39%FEMYFemasys65.27%PYPDPolyPid26.47%WOKWORK Medical Technology Group LTD Ordinary SharesN/AInsider OwnershipCompanyInsider OwnershipDRIODarioHealth10.90%FEMYFemasys12.32%PYPDPolyPid24.70%WOKWORK Medical Technology Group LTD Ordinary SharesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRIODarioHealth20044.45 million28.47 millionOptionableFEMYFemasys3027.24 million20.08 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataWOKWORK Medical Technology Group LTD Ordinary Shares22614.59 millionN/AN/AWOK, DRIO, PYPD, and FEMY HeadlinesRecent News About These CompaniesUnivest Securities, LLC Announces Closing of $5 Million Registered Offering for its Client WORK Medical Technology Group LTD (NASDAQ: WOK)May 22, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Closing of Registered OfferingMay 22, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Pricing of Registered OfferingMay 21, 2025 | globenewswire.comWORK Medical Technology Group LTD Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 11, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Implementation of Dual-Class Share Structure Effective March 6, 2025March 5, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.February 28, 2025 | globenewswire.comWORK Medical Technology Group LTD Reports Financial Results for Fiscal Year 2024February 14, 2025 | prnewswire.comWORK Medical Technology Group LTD's Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024November 27, 2024 | globenewswire.comWORK Medical Technology Group LTD Announces Partial Exercise of Underwriters' Over-Allotment OptionAugust 29, 2024 | globenewswire.comWORK Medical Technology Group LTD Announces Closing of Initial Public OfferingAugust 26, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumWhy Energy Stocks Like Exxon and Hess Are Back in FocusBy Gabriel Osorio-Mazilli | May 4, 2025View Why Energy Stocks Like Exxon and Hess Are Back in FocusWOK, DRIO, PYPD, and FEMY Company DescriptionsDarioHealth NASDAQ:DRIO$0.70 +0.00 (+0.66%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.69 -0.01 (-1.71%) As of 05/29/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Femasys NASDAQ:FEMY$1.02 -0.04 (-3.77%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.92 -0.10 (-10.00%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.PolyPid NASDAQ:PYPD$2.79 +0.25 (+9.84%) Closing price 05/29/2025 03:59 PM EasternExtended Trading$2.84 +0.05 (+1.79%) As of 05/29/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.WORK Medical Technology Group LTD Ordinary Shares NASDAQ:WOK$0.87 +0.07 (+8.78%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.85 -0.02 (-2.53%) As of 05/29/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
